IceCure Medical has begun its post-marketing study for a low-risk breast cancer treatment at its first United States clinical site, the company announced through PR Newswire. The study, called ChoICE, will evaluate the company's cryoablation technology, which uses extreme cold to destroy tumor tissue.
Cryoablation is a minimally invasive procedure that freezes and kills abnormal cells without the need for traditional surgery. For patients with low-risk breast cancer, the approach offers a potential alternative to surgical removal of tumors, which can carry longer recovery times and greater physical impact.
The ChoICE study is a post-marketing study, meaning it takes place after the technology has already received regulatory clearance. Post-marketing studies are designed to collect real-world data on how a treatment performs outside of the controlled conditions of a clinical trial.
IceCure Medical is an Israel-based medical device company that has been developing cryoablation technology for several years. The company's ProSense system delivers liquid nitrogen through a thin needle-like probe directly into the tumor, freezing it in place.
The launch at the first U.S. clinical site marks a significant step in the company's efforts to expand adoption of the technology in the American healthcare market. The United States represents one of the largest markets for breast cancer treatment globally, given the high volume of diagnoses each year.
Low-risk breast cancer typically refers to small, early-stage tumors that are hormone receptor positive and have a low likelihood of spreading. Patients in this category are often candidates for less aggressive treatment approaches, making them a logical target population for a minimally invasive option like cryoablation.
The company has not yet released details about how many patients the ChoICE study aims to enroll or the full timeline for data collection. Results from the study are expected to contribute to the broader evidence base supporting cryoablation as a standard treatment option for eligible breast cancer patients.
